Cisplatin Nephrotoxicity: New Insights in an Old Problem

Main Article Content

Ioannis Koulouridis Efstathios Koulouridis

Abstract

Cis-diamino-dichloro platinum is one of the most widely used antineoplastic drugs. It is used therapeutically in 10-20% of all cancers. It is active against a variety of solid tumors such as head, neck, lungs, ovaries, cervix, bladder, etc. The therapeutic use of the drug is combined with significant toxicities such as: neurotoxicity (85-95%), ototoxicity (23-50%), nephrotoxicity (30%), gastrotoxicity and bone marrow suppression.


Nephrotoxicity is a limiting condition since repeated episodes of acute kidney injury may lead to chronic kidney disease which then develops regardless of drug discontinuation. Unfortunately, nephrotoxicity and antineoplastic activity share common molecular mechanisms at the cellular level. Therefore, any attempt to reduce nephrotoxicity implies a reduction in the antineoplastic effect.


Continuing investigation of the mechanisms underlying cisplatin nephrotoxicity upon molecular level has provided an enormous amount of knowledge concerning accumulation of the drug in renal epithelial cells, cellular damage via destruction of cellular organelles and cellular proteins as well as induction of repair and rescue mechanisms such as autophagy toward the improvement of cell survival. All these metabolic pathways are currently candidates for therapeutic intervention. Moreover, new therapeutic approaches based upon natural derivatives such as phytochemicals are under laboratory investigation hopping to add more effective treatments in cisplatin nephrotoxicity.  


In the present review we analyze the mechanisms of drug-induced cellular damage, the evidence so far, and developments in the effort to reduce nephrotoxicity without loss of drug activity.

Article Details

How to Cite
KOULOURIDIS, Ioannis; KOULOURIDIS, Efstathios. Cisplatin Nephrotoxicity: New Insights in an Old Problem. Medical Research Archives, [S.l.], v. 10, n. 3, mar. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2725>. Date accessed: 06 dec. 2022. doi: https://doi.org/10.18103/mra.v10i3.2725.
Section
Research Articles

References

1. Luis Alberto Batista Peres, Ademar Dantas de Cunha Jr. Acute nephrotoxicity of Cisplatin: Molecular mechanisms. J Bras Nephrol. 2013; 35(4): 332-340.
2. Motohashi H, Inui KI. Organic cation transporters OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013; 15 2013; (2): 581-588.
3. Miller RP, Tadagavadi RK, Ramesh G, ReevesWB. Mechanisms of Cisplatin nephrotoxicity. Toxins.2010; (2): 2490-2518.
4. Kaushal GR, Kaushal V, Herzog C, et al. Autophagy delays apoptosis in renal tubular epithelial cells in Cisplatin cytotoxicity. Autophagy 2008; 4 (5): 710-712.
5. Kauffman GB, Pendimalli R, Doldi S, et al. Hall MD. (2010): Michele Peyrone (1813-1883), discoverer of Cisplatin. Platinum metals rev. 2010; 54 (41): 250-256.
6. Rosenberg B, VanCamp L, Krigas T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature 1965; 205: 698 – 699.
7. Rosenberg B, VanCamp L, Trosko JE, et al. Platinum Compounds: a New Class of Potent Antitumor Agents. Nature 1969; 222: 385-386.
8. Madias NE. Platinum nephrotoxicity. Am J Med 1978; 65: 307-314.
9. Latcha S, Jaims EA, Patil S, et al. Long-term renal outcomes after Cisplatin treatment. Clin J Am Soc Nephrol. 2016; 11: 1173-1179.
10. Hartman JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866-869.
11. Galfetti E, Cerutti A, Ghielimini M, et al. Risk factors of renal toxicity after in patient Cisplatin administration. BMC Pharmacol Toxicol. 2020; 21,19 (2020).
12. Sasaki T, Motoyama S, Komatsuda A, Shibata H, Sato Y, Yoshino K et al. Two cases of Cisplatin-induced permanent renal failure following neoadjuvant chemotherapy for esophageal cancer. Int J Surg Case Rep.2016; 20: 63-67.
13. Klemens Meyer BMKB, Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab.1995; 20: 201-213.
14. Khan MAH, Sattar MA, Addullah NA, et al. Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness. Exp Toxicol Pathol. 2007; 59(3-4): 253-260.
15. Daugaard G, Abildgaard U, Holstein-Rathlou NH, et al. Effect of Cisplatin on renal haemodynamics and tubular function in the dog kidney. Int J Andrology 1987; 10: 347-351.
16. Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, et al. Electrolyte disorders with platinum chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017; 80: 895-907.
17. Gately DT, Howell SB. Cellular accumulation of the anticancer agent Cisplatin: a review. Br J Cancer 1993; 67: 1171-1176.
18. Eljack ND, Ma HYM, Drucker J, et al. Mechanisms of cell uptake and toxicity of the anticancer Cisplatin. Metallomics 2014; 6: 2126-2133.
19. Harrach S, Ciarimboli G. Role of transporters in the distribution of platinum-based drugs. Front Pharmacol. 2015; 6: 85.
20. Sprowl JA, van Doom L, Hu S, van Gerven L, de Bruijn P, Gibson AA, et al. Conjunctive therapy of Cisplatin with the OCT2 inhibitor Cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther. 2013; 94(5): 585-592.
21. Carvalho Rodrigues MA, dos Santos NAG, da Silva Faria MC, Rodrigues JL, Kinoshita A, Baffa O, et al. Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of Cisplatin. Chemico-Biological Interactions 2016; 245: 59-65.
22. Guo D, Yang H, Li Q, Bae JH, Obianom O, Zeng S, et al. Selective inhibition on organic cation transporters by Carvedilol protects mice from Cisplatin-induced nephrotoxicity. Pharm Res.2018; 35(11): 204.
23. Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007; 334(2): 115-124.
24. Jamieson ER, Lippard SJ. Structure, recognition, and processing of Cisplatin-DNA adducts. Chem Rev. 1999; 99: 2457-2498.
25. Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, et al. Molecular mechanisms of Cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 2019; 26(1): 25.
26. Yang C, Kaushal V, Shah SV, et al. Autophagy is associated with apoptosis in Cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol. 2008; 294: F777-F787.
27. Kaushal GP, Kaushal V, Herzog C, et al. Autophagy delays apoptosis in renal tubular epithelial cells in Cisplatin cytotoxicity. Autophagy 2008; 4 (5): 710-712.
28. Klionsky DJ. Autophagy revisited: a conversation with Christian de Duve. Autophagy 2008; 4:6, 740-743.
29. White E. (2016): Autophagy and p53. Cold Spring Harb Perspect Med 2016;6:a026120.
30. Elmore S. Apoptosis: a review of programed cell death. Toxicol. Pathol. 2007; 35(4):495-516.
31. Aubrey BJ, Kelly GL, Janic A, et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 2018; 25: 104-113.
32. Jiang M, Yi X, Hsu S, Wang C-Y, Dong Z. Role of p53 in Cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol. 2004; 287: F1140-F1147.
33. Cummings BS, Schnellman RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and-independent pathways. J Pharmacol Exp Ther. 2002; Jul; 302(10): 8-17.
34. Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, et al. Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol. 2018; 22:210-244.
35. Crona DJ, Faso A, Nishuima TF, et al. McGraw KA, Galsky MD. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. The Oncologist 2017; 22: 609-619.
36. Ojha S, Venkataraman B, Kurdi A, et al. Plant-Derived Agents for Counteracting Cisplatin-Induced Nephrotoxicity. Oxid Med Cell Longev.2016; 2016: 4320374.
37. Mi X-J, Hou J-G, Wang Z, Han Y, Ren S, Hu J-N, et al. The protective effects of maltol on Cisplatin-induced nephrotoxicity through the AMPK-mediated PI3K/Akt and p53 signaling pathways. Sci Rep. 2018; Oct 29; 8(1): 15922.